Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis
Nitin Ohri, Balázs Halmos, William Bodner, Haiying Cheng, Madhur Garg, Rasim Gucalp, Chandan Guha
Topics & Concepts
DurvalumabMedicineChemoradiotherapyAdjuvantLung cancerOncologyExploratory analysisInternal medicineCancerImmunotherapyPembrolizumabData scienceComputer scienceCancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease PrognosisLung Cancer Diagnosis and Treatment